Navigation Links
BRG1 mutations confer resistance to hormones in lung cancer
Date:3/15/2012

Retinoic acid (vitamin A) and steroids are hormones found in our body that protect against oxidative stress, reduce inflammation and are involved in cellular differentiation processes. One of the characteristics of tumours is that their cells have lost the ability to differentiate; therefore these hormones have useful properties to prevent cancer. Currently, retinoic acid and steroids are being used to treat some types of leukaemia.

A study led by the research group on Genes and Cancer of the Bellvitge Biomedical Research Institute (IDIBELL) has shown that the loss of BRG1 gene implies a lack of response of cells to these hormones, and therefore the tumour may continue growing. Study results have been published in the journal EMBO Molecular Medicine.

BRG1 gene

The IDIBELL research group on Genes and Cancer led by Montse Sanchez-Cespedes discovered some years ago that the BRG1 gene, a tumour suppressor, is inactivated in non-small cell lung cancer by genetic mutations. "The BRG1 protein is part of a chromatin remodelling complex that regulates the expression of several genes", explains the researcher, "and it is related to the differentiation of lung cells, allowing cells response to certain hormones and environment vitamins like vitamin A or steroids."

When BRG1 is mutated and therefore inactive, tumour cells do not respond to the presence of these hormones and they continue growing and spreading. For this reason, these types of tumours are refractory to the treatment with these substances.

Clinic Application

"At the moment", says Montse Sanchez-Cespedes, "we are not able to restore the functionality of a tumour suppressor gene as BRG1 in patients. Therefore, we are still far from a therapeutic application but this discovery enables us to understand better the biology of tumours. What we will try to do in the immediate future is to look for agents that specifically destroy the cells with mutated BRG1, following the strategy of lethal synthetics".

In any case, this finding it can be useful in advancing personalized medicine, because "it explains why lung cancer patients are resistant to these treatments and may serve to rule out therapies with lipid-derived hormones in patients with BRG1 mutations, not just in lung cancer but also in breast and prostate, among others."


'/>"/>

Contact: Arantxa Mena
comunicacio@idibell.cat
IDIBELL-Bellvitge Biomedical Research Institute
Source:Eurekalert

Related biology news :

1. Researchers discover gene mutations that cause childhood brain cancer
2. Penn biologists discover how silent mutations influence protein production
3. Rapid approach to identify influenza A virus mutations and drug resistance developed
4. Further gene mutations linked to autism risk
5. DNA mutations linked to diabetes
6. Species diversity helps ASU researchers refine analyses of human gene mutations
7. Study of huge numbers of genetic mutations point to oxidative stress as underlying cause
8. Penn biologists explain how organisms can tolerate mutations, yet adapt to environmental change
9. Mutations in different cells cooperate to set the stage for cancer
10. Supplement blocks the initiation of breast cell mutations by estrogens
11. Scripps Research scientists reveal how genetic mutations may cause type 1 diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/15/2016)... 15, 2016  Synthetic Biologics, Inc. (NYSE MKT: ... on the gut microbiome, today announced the pricing ... of its common stock and warrants to purchase ... price to the public of $1.00 per share ... from the offering, excluding the proceeds, if any ...
(Date:6/27/2016)... 2016 Research and Markets has announced the ... report to their offering. The ... to grow at a CAGR of 12.28% during the period ... an in-depth market analysis with inputs from industry experts. The report ... years. The report also includes a discussion of the key vendors ...
(Date:6/21/2016)... Columbia , June 21, 2016 ... to the new role of principal product architect ... named the director of customer development. Both will ... chief technical officer. The moves reflect NuData,s strategic ... in response to high customer demand and customer ...
Breaking Biology News(10 mins):
(Date:11/30/2016)... Mass. , Nov. 30, 2016   Merck ... that it has entered into a set of agreements ... services for Merck,s collection of genetic reagents such as ... with Evotec,s screening expertise offers an accelerated pathway to ... discovery starts with the identification of new targets, a ...
(Date:11/30/2016)... ... November 30, 2016 , ... Energetiq Technology, a world leader ... generation, ultra-bright, Laser-Driven Light Source, the EQ-77, at the MRS Fall Exhibit 2016. ... offers higher radiance and irradiance from a truly broadband white light source. The ...
(Date:11/30/2016)... ... November 30, 2016 , ... On 28 November 2016, the International Union ... nihonium (Nh), moscovium (Mc), tennessine (Ts), and oganesson (Og), respectively for element 113, ... earlier proposed by the discoverers have been approved by the IUPAC Bureau. The IUPAC ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... of precision treatments for neurodegenerative diseases, today announced that all five of its ... 3, 2016) blocked propagation of toxic, prion-like forms of Amyloid beta (Aß) in ...
Breaking Biology Technology: